行情

GNCA

GNCA

Genocea
NASDAQ

实时行情|Nasdaq Last Sale

1.804
+0.044
+2.51%
交易中 15:50 04/08 EDT
开盘
1.760
昨收
1.760
最高
1.830
最低
1.739
成交量
7.96万
成交额
--
52周最高
11.28
52周最低
1.100
市值
4,987.21万
市盈率(TTM)
-0.7954
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GNCA价格均价为16.40,最高价位32.00,最低价为7.00。

EPS

GNCA 新闻

更多
  • Genocea Biosciences (GNCA) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 03/17 21:44
  • How Not To Day Trade
  • Benzinga · 03/06 17:44
  • UPDATE: Hearing Genocea Granted European Patent EP2665490 For 'Vaccines And Compositions Against Streptococcus Pneumoniae'
  • Benzinga · 03/04 15:19
  • The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
  • Benzinga · 02/28 12:28

所属板块

生物技术和医学研究
+3.44%
制药与医学研究
+3.44%

热门股票

代码
价格
涨跌幅

GNCA 简况

Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.
展开

微牛提供Genocea Biosciences Inc(NASDAQ-GNCA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GNCA股票新闻,以帮助您做出投资决策。